Source:http://linkedlifedata.com/resource/pubmed/id/10063997
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-6-4
|
| pubmed:abstractText |
We studied the safety and efficacy of treatment with continuous infusion of a von Willebrand factor (vWF) concentrate Haemate-P in patients with von Willebrand disease (vWD). Three patients with mild and 5 patients with severe forms of vWD, were treated with continuous infusion of Haemate-P by minipump. The indications for treatment were: to prevent bleeding during 9 surgical procedures or 1 vaginal delivery in 6 patients and to treat 2 bleeding episodes in 2 patients. The patients were monitored daily for factor VIII (FVIII:C) and ristocetin cofactor (vWF: RCo) levels and the infusion rate was adjusted to maintain the desired therapeutic level of vWF:RCo. The treatment was effective in preventing surgical bleeding and controlling bleeding episodes. All factor VIII:C and most of the vWF:RCo levels measured during the study period were above the target therapeutic levels. A significant decrease in clearance of FVIII:C and vWF:RCo was observed over the treatment period. Haemate-P consumption averaged 24.3+/-7.9 vWF:RCo U/kg/day which is approximately half the expected dose had intermittent bolus injections been used. We suggest that continuous Haemate-P infusion is superior to intermittent bolus injections for the treatment of vWD patients by virtue of its efficiency, simplicity and considerable savings.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
81
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
229-33
|
| pubmed:dateRevised |
2009-11-19
|
| pubmed:meshHeading |
pubmed-meshheading:10063997-Adolescent,
pubmed-meshheading:10063997-Adult,
pubmed-meshheading:10063997-Blood Loss, Surgical,
pubmed-meshheading:10063997-Cesarean Section,
pubmed-meshheading:10063997-Child,
pubmed-meshheading:10063997-Factor VIII,
pubmed-meshheading:10063997-Female,
pubmed-meshheading:10063997-Humans,
pubmed-meshheading:10063997-Infusion Pumps,
pubmed-meshheading:10063997-Infusions, Intravenous,
pubmed-meshheading:10063997-Male,
pubmed-meshheading:10063997-Middle Aged,
pubmed-meshheading:10063997-Pregnancy,
pubmed-meshheading:10063997-Pregnancy Complications, Hematologic,
pubmed-meshheading:10063997-Preoperative Care,
pubmed-meshheading:10063997-Safety,
pubmed-meshheading:10063997-Surgical Procedures, Elective,
pubmed-meshheading:10063997-Treatment Outcome,
pubmed-meshheading:10063997-von Willebrand Diseases,
pubmed-meshheading:10063997-von Willebrand Factor
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
|
| pubmed:affiliation |
Institute of Thrombosis and Hemostasis and National Haemophilia Center, Sheba Medical Center, Tel-Hashomer, Israel.
|
| pubmed:publicationType |
Journal Article
|